In end-December 2018, leading pharmaceutical packaging company Schott Kaisha has launched a highly specialized glass syringe portfolio in India, which further minimizes the risk of drug/container interactions for sensitive drugs. As part of its German partner Schott’s iQ platform, syriQ BioPure is a hugely customizable glass prefillable staked-needle syringe (PFS) specifically designed to keep sensitive drugs stable over their shelf life and shorten time to market while making administration more convenient for patients.
Complex biotech drugs always face a threat of interacting with their container system. These interactions cannot be predicted and can lead to unintentional aggregation or deterioration of the drug which may eventually compromise the total cost of ownership, shelf life of the drug and treatment efficiency.
Rishad Dadachanji, director, Schott Kaisha shares, “The syriQ BioPure syringes, manufactured in St. Gallen, Switzerland, combine features to ensure stability and safe administration of sensitive drugs. Our clients often work with complex biologicals that require an extremely reliable PFS solution. We are happy with the response that this offering is receiving from our existing and potential clients.”
A Quality by Design approach, benchmark manufacturing and quality control processes using breakthrough inspection technology, combined with best-inclass components have established syriQ BioPure as a preferred container solution globally. Its application has proven to be beneficial in achieving ultra-low tungsten residuals (ICP-MS certificate available); uniform silicon layer; low adhesive residuals; and, low E&L from latest high-quality elastomer formulations.
The new glass syringes work with leading safety and autoinjector devices, meeting market demand for products that can be administered at home for patient comfort. Seamless integration into these devices is reached thanks to the syringe’s high dimensional accuracy.
